• LAST PRICE
    3.9100
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    3.1900/ 3
  • Ask / Lots
    3.9800/ 1
  • Open / Previous Close
    0.0000 / 3.9100
  • Day Range
    ---
  • 52 Week Range
    Low 1.9400
    High 8.4700
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 3.57
TimeVolumeDSGN
09:32 ET12493.5
09:36 ET4003.55
09:39 ET15153.56
09:41 ET1003.55
09:43 ET5003.55
09:50 ET1313.56
09:54 ET25603.54
09:57 ET1003.5225
09:59 ET5003.545
10:01 ET10593.5401
10:06 ET2003.54
10:15 ET4003.545
10:17 ET4003.56
10:19 ET2003.57
10:21 ET6003.57
10:24 ET3003.565
10:26 ET6003.57
10:28 ET2003.575
10:30 ET1003.58
10:32 ET10003.59
10:33 ET37003.595
10:35 ET82653.6
10:37 ET2003.59
10:42 ET3003.5825
10:44 ET16003.59
10:46 ET4063.595
10:48 ET4003.6
10:51 ET2003.595
10:55 ET1003.5993
10:57 ET20613.605
11:00 ET5003.605
11:02 ET1003.61
11:04 ET8003.62
11:08 ET2003.63
11:11 ET9003.6499
11:13 ET2753.655
11:18 ET2733.67
11:20 ET14223.6799
11:22 ET21703.705
11:24 ET3003.71
11:26 ET46213.695
11:27 ET58763.71
11:33 ET12003.7199
11:36 ET9603.7297
11:38 ET4003.75
11:40 ET14773.746
11:42 ET20543.745
11:44 ET3003.7408
11:45 ET1003.75
11:47 ET12003.75
11:49 ET1003.75
11:51 ET1003.75
11:54 ET19003.76
11:56 ET157363.77
11:58 ET106003.765
12:00 ET1003.77
12:02 ET22003.78
12:03 ET9003.8
12:05 ET36513.785
12:09 ET14003.79
12:12 ET1003.8
12:14 ET99823.78
12:16 ET1003.775
12:18 ET51303.79
12:20 ET13003.8
12:23 ET9193.81
12:25 ET9623.82
12:27 ET1003.83
12:30 ET35543.8
12:32 ET105003.7925
12:34 ET14843.8091
12:36 ET13003.81
12:38 ET4973.82
12:39 ET6403.825
12:41 ET4003.8252
12:45 ET6003.825
12:48 ET9973.835
12:50 ET36793.8406
12:56 ET34983.86
12:57 ET27913.87
12:59 ET7003.88
01:01 ET2283.8889
01:03 ET3003.89
01:06 ET6503.885
01:08 ET73593.8988
01:10 ET8503.9093
01:12 ET11003.915
01:14 ET51043.9
01:15 ET4963.88
01:17 ET3683.88
01:19 ET19683.901
01:24 ET15003.89
01:26 ET27573.86
01:28 ET1003.86
01:30 ET8003.85
01:32 ET10003.84
01:35 ET13013.8407
01:37 ET10573.85
01:39 ET1073.84
01:42 ET21003.835
01:44 ET6003.84
01:46 ET1003.85
01:48 ET3353.855
01:50 ET7003.86
01:53 ET6003.88
01:55 ET12153.875
01:57 ET8003.88
02:00 ET9003.89
02:02 ET1993.89
02:04 ET1003.885
02:08 ET32803.88
02:09 ET4453.8799
02:11 ET10173.89
02:15 ET42853.87
02:18 ET14003.8777
02:20 ET5003.87
02:22 ET6003.86
02:24 ET11003.87
02:26 ET3053.885
02:27 ET2003.89
02:29 ET2003.9
02:31 ET15493.9
02:36 ET2003.9
02:42 ET3273.9
02:44 ET10003.895
02:45 ET36003.89
02:47 ET1003.9
02:49 ET4423.9
02:54 ET1003.9
02:56 ET2003.895
03:00 ET4503.8912
03:02 ET1003.9
03:03 ET37463.91
03:05 ET149873.89
03:07 ET45003.91
03:09 ET15943.905
03:14 ET25103.9
03:16 ET4283.905
03:18 ET8003.91
03:21 ET2003.91
03:23 ET1003.905
03:25 ET1003.91
03:32 ET1003.91
03:36 ET2003.9025
03:38 ET1273.9088
03:41 ET2003.91
03:43 ET38663.9089
03:48 ET10603.905
03:50 ET7673.91
03:52 ET2003.905
03:54 ET6143.91
03:56 ET29513.92
03:57 ET24853.9292
03:59 ET203223.91
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesDSGN
Design Therapeutics Inc
220.9M
-3.3x
---
United StatesOMER
Omeros Corp
215.0M
-1.2x
---
United StatesMACK
Merrimack Pharmaceuticals Inc
214.3M
-178.6x
---
United StatesOVID
Ovid Therapeutics Inc
215.7M
-4.1x
---
United StatesATOS
Atossa Therapeutics Inc
229.3M
-7.8x
---
United StatesATNM
Actinium Pharmaceuticals Inc
217.7M
-4.1x
---
As of 2024-03-28

Company Information

Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. The Company is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its HD program is focused on the development of a potentially disease-modifying treatment for HD.

Contact Information

Headquarters
6005 Hidden Valley Road, Suite 110CARLSBAD, CA, United States 92011
Phone
858-293-4900
Fax
302-636-5454

Executives

Chairman of the Board, President, Chief Executive Officer, Principal Financial Officer
Pratik Shah
Co-Founder
Aseem Ansari
Chief Operating Officer
Sean Jeffries
Lead Independent Director
Simeon George
Independent Director
Heather Berger

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$220.9M
Revenue (TTM)
$0.00
Shares Outstanding
56.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-1.19
Book Value
$4.92
P/E Ratio
-3.3x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.